Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
4 Sound blocking Earphones for Prevalent Sound and Solace - 2Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- 3Most loved Web-based feature: Which Stage Do You Like
- 4How to watch 'A Charlie Brown Christmas' for free this weekend
- 5Figure out How to Stay away from Normal Handshaking Missteps
- Dave Coulier shares new cancer diagnosis 1 year after revealing previous diagnosis
- Famous SUVs With Low Energy Utilization In 2024
- The Most Encouraging New companies to Look Out For
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- Famous Restroom Beautifying Styles For 2024
- Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- Tech Patterns 2023: 12 Advancements to Keep an eye Out For
- The most effective method to Guarantee Thorough Inclusion in Senior Protection.
- Instructions to Construct an Organization While Chasing after a Web-based Degree
